Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

IPOG

Financiado

Cerrado

Improving Pregnancy Outcomes Gloablly

Preeclampsia is responsible for the deaths of more than 70,000 mothers and half a million babies each year. Identifying those mothers at risk of preeclampsia is difficult. The current gold standard in prenatal care does not detect... ver más

31/01/2021

METABOL

3M€

Presupuesto del proyecto: 3M€

Líder del proyecto

METABOLOMIC DIAGNOSTICS LIMITED No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2021-01-31

EIC-SMEInst-2018-2020: SME instrument

I+D

Cerrada hace 7 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

METABOL

1.89M€ | Lider

ZUAZO

299.44K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PTQ-16-08454 Desarrollo de un modelo predictivo para el diagnóstico preco... 86K€ Cerrado

IMPROvED IMPROvED IMproved Pregnancy Outcomes by Early Detection pe... 8M€ Cerrado

ASPRE Combined Multi marker Screening and Randomised Patient Treat... 8M€ Cerrado

PREKIND PreEclampsia diagnosis by Early Kidney Injury Detection 71K€ Cerrado

HealthierWomen A woman s reproductive experience Long term implications fo... 3M€ Cerrado

PRECALI PREeclampsia risk stratification test development of a suit... 176K€ Cerrado

Duración del proyecto: 27 meses Fecha Inicio: 2018-10-24
Fecha Fin: 2021-01-31

Líder del proyecto

METABOLOMIC DIAGNOSTICS LIMITED No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 3M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Preeclampsia is responsible for the deaths of more than 70,000 mothers and half a million babies each year. Identifying those mothers at risk of preeclampsia is difficult. The current gold standard in prenatal care does not detect the disease early enough to change the course of the disease. MDx has developed PrePsia™, a simple blood test which identifies an expectant mother’s risk of preterm preeclampsia, up to 5 months before most women will display clinical symptoms. Clinicians can now use this simple tool, to personalise pregnancy care, including the initiation of treatments in early pregnancy that can dramatically reduce the incidence of preterm preeclampsia by 62%3. In the EU, with about 5.1 million births per annum (2015 data) , treating the women identified at high risk for preterm preeclampsia by PrePsia™ has the potential to prevent over 37,000 cases of preterm preeclampsia and its associated severe outcomes, every year. The only other test in the market that screens for preterm preeclampsia, is complex and requires for specialist ultrasound scans to be taken, which are expensive, subjective and require for dedicated ultrasound equipment and operators. MDx has a portfolio of IP assets, as developed by the company over the last 5 years, that will protect PrePsia™ and also have significant commercial potential beyond just the realm of preeclampsia. MDx has team of successful serial entrepreneurs coupled with globally renewed technical expertise to deliver PrePsia™ to the market and build a long term self-sustaining European company. By year 4 MDx will have annualised revenues of €69 million and employment for 50 people while fulfilling its ambition to become a world leader in innovative pregnancy diagnostics.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores